View printer-friendly version |
Charles River Laboratories Plans to Increase CRADL Capacity in Cambridge
CRADL is the leading space for clients to launch or expand their drug research programs, with the added benefit of access to Charles River’s complete portfolio of integrated drug discovery and non-clinical development resources.
Increasing Space for
CRADL’s flagship location on
Both locations offer rental vivarium space for both emerging and established biopharmaceutical companies and research institutions, allowing scientists to focus on research, while leaving the animal husbandry and daily vivarium management to a trusted partner. By offering turnkey, on-demand facilities, clients are able to quickly start new projects, accelerating the early stage of research.
More Than a Vivarium
To further support the
Approved Quotes
-
“In the biopharmaceutical industry, both infrastructure and staffing can be prohibitively expensive and take significant time to develop. CRADL alleviates that burden by providing best-in-class vivarium space and management to both emerging and established institutions. By outsourcing their vivarium space, researchers can focus on research, instead of logistics.” –
Julie Freebersyser , DVM, DACLAM, Director of CRADL Operations at Charles River -
“For over 70 years, Charles River has supplied the research community with industry-leading products and services. When clients utilize our CRADL spaces, they not only gain access to industry-leading vivarium management, they also have access to Charles River’s complete portfolio to accelerate their next major discovery.” –
David Leroux-Petersen , Corporate Vice President, North America Research Models and Services & Global Avian Vaccine Services at Charles River
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005110/en/
Investor Contact:
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com
Media Contact:
Chief Communications Officer
781-222-6168
amy.cianciaruso@crl.com
Source: